NRx Pharmaceuticals, Inc. (NRXP)
NRXPNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$2.34
-0.0400 (-1.68%) today
At the close, Nov 10, 4:00 PM ET. After hours $2.38 +0.85%
- Market cap
- $103.01m
- P/E
- –
- EPS, last 4 quarters
- $-0.2100
- Dividend yield
- –
- Day range
- $2.29 to $2.40
- 52-week range
- $1.62 to $5.06
- Average volume
- 1.07m
- Previous close
- $2.38
Analysts
3 coveringHold3 buy, 0 hold, 0 sell
Targets a year out average $35.33, +1409.8% from here
Earnings
next estimate $-0.2900Next report Nov 13, 2026
Sep 2025
-63.6%
Dec 2025
+311.1%
Mar 2026
+20.0%
Jun 2026
-100.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $242.0k | $983.0k | $1.07m | $1.10m |
| Gross profit | $145.0k | $575.0k | $437.0k | $426.0k |
| Operating income | -$4.02m | -$4.62m | -$4.74m | -$6.51m |
| Net income | -$5.89m | $360.0k | -$1.43m | -$16.52m |
Last four quarters: revenue $3.39m, margin -691.8%, free cash flow –
News
8 latest- NRx Pharmaceuticals Wins FDA Approval for Preservative-Free Ketamine InjectionMarketBeat · Oct 30, 2026
- NRx Pharmaceuticals Secures FDA Nod For Preservative-Free Ketamine Ahead Of Target Date; Stock Up RTTNews · Oct 30, 2026
- Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Q2 Earnings Lag EstimatesZacks · Oct 29, 2026
- Biotech Stocks Facing FDA Decision In November 2026 RTTNews · Oct 29, 2026
- NRx Pharmaceuticals Targets November FDA Deadline For Preservative-Free Ketamine RTTNews · Oct 15, 2026
- NRx Pharmaceuticals Receives FDA Label Revision Request For Its Preservative-Free Ketamine Product RTTNews · Oct 15, 2026
- Ono Pharmaceutical Co. (OPHLF) Soars 13.9%: Is Further Upside Left in the Stock?Zacks · Sep 24, 2026
- NRx Pharmaceuticals Reports FDA Reclassifies Ketamine Amendment As Minor RTTNews · Sep 16, 2026
The company
NRx Pharmaceuticals, Inc. ( www.nrxpharma.com ), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA receptor platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company has been awarded a Abbreviated New Drug Approval (ANDA) for Preservative-Free Ketamine and is seeking New Drug Approval for a presentation of intravenous ketamine (NRX-100) with approved claims for treating depression and suicidality.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- nrxpharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.